Steven Scott West

home / authors / steven-scott-west

Articles

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO

The Investigational Pipeline for Advanced BTC

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ;Steven Scott West

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Factoring in Trastuzumab Deruxtecan in the Advanced BTC Setting

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ;Steven Scott West

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss how to factor in trastuzumab deruxtecan in advanced biliary tract cancer.

Considering Factors When Choosing Among IO Agents in Advanced BTC

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ;Steven Scott West

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.

Clinical Implications of 3-Year OS Data With Durvalumab/Chemo in Advanced BTC

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ;Steven Scott West

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the clinical implications of 3-year survival data from TOPAZ-1 in advanced biliary tract cancer.

Milind Javle, MD; and Rachna Shroff, MD, MS, FASCO

Putting TOPAZ-1 Data into Context for Patients With Advanced BTC

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ;Steven Scott West

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient put the TOPAZ-1 data into context for patients with advanced biliary tract cancer.

Homing in on the TOPAZ-1 Trial in Biliary Tract Cancer

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ;Steven Scott West

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Discussion of a Patient Case of Advanced BTC

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ;Steven Scott West

May 29th 2024

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, discuss a case of advanced biliary tract cancer with a patient.

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; Steven Scott West

Prognosis and Standards of Care in Advanced Biliary Tract Cancer

Milind Javle, MD, The University of Texas MD Anderson Cancer Center;Rachna T. Shroff, MD, MS, FASCO, University of Arizona Cancer Center ;Steven Scott West

May 29th 2024

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, and a patient discuss prognosis and standard-of-care treatment for patients with advanced biliary tract cancer.